, Volume 14, Issue 6, pp 483-485
Date: 01 Sep 2012

Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Our commentary is prompted by the recent release of information on the two most promising areas of drug development in the treatment of ovarian cancer: the vascular endothelial growth factor inhibitor bevacizumab and the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor olaparib. Firstly, positive results, chiefly in terms of progression-free survival (PFS), have now been reported for bevacizumab in both first-line and recurrent/resistant disease settings. This has led many clinicians to conclude that the agent should now be incorporated into the standard management of this disease. On the other hand, a press release in December 2011 indicated that the development of olaparib in serous ovarian cancer was in question following a review of an interim analysis of a phase II study (Study 19) [1]. This had indicated that in a maintenance therapy trial, the previously reported PFS benefit was unlikely to translate into an overall survival (OS) benefit. This press release led to ...